-
Mashup Score: 1Low anti-TNF concentrations at week 14 linked to long-term loss of response in Crohn’s - 10 hour(s) ago
Approximately two-thirds of patients with Crohn’s disease who initially responded to anti-tumor necrosis factor therapy lost response by 3 years, with researchers suggesting that higher drug concentrations at induction may improve outcomes. “Anti-TNF treatment failure is common, with a quarter of patients having primary nonresponse and a third of initial responders losing
Source: www.healio.comCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 2Anti-TNF use linked to risk for progressive kidney function decline in patients with IBD - 1 day(s) ago
Tumor necrosis factor inhibitor use was independently associated with a greater risk for progressive kidney function decline but not risk for all-cause mortality among patients with new-onset inflammatory bowel disease, according to data. “To date, a number of studies have reported favorable effects of anti-TNF therapy on the extraintestinal manifestations of IBD,” Keiichi Sumida, MD,
Source: www.healio.comCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 0Diagnosis, treatment of celiac disease via screening program improves outcomes in children - 2 day(s) ago
Children diagnosed with celiac disease and treated through a statewide screening program experienced improvements in initially unrecognized symptoms and quality of life, as well as greater adherence to a gluten-free diet, research showed. “Despite increasing prevalence and often delayed diagnosis, mass screening for CD remains controversial,” Marisa G. Stahl, MD, MSCS, assistant
Source: www.healio.comCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 0
A pharmacy-based, multicomponent intervention program reduced proton pump inhibitor use overall and also when appropriate for gastroprotection, with little evidence of either clinical harms or benefits, according to a study in BMJ. “PPIs are one of the most commonly prescribed classes of drugs, but an estimated 25% to 70% of PPI users may not have an appropriate indication, depending on the
Source: www.healio.comCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 0
In a Healio video exclusive, Wendi LeBrett, MD, winner of the 2023 Healio Social Media Influencer Award, discusses how she uses social media, namely TikTok, to address misleading or inaccurate information about gastrointestinal diseases. “Part of my inspiration for doing this was to correct medical misinformation online,” LeBrett, a third-year GI fellow at UCLA Health, told Healio.
Source: www.healio.comCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 1Colonoscopy screening gap ‘could potentially be extended’ to 15 years for average-risk CRC - 5 day(s) ago
The 10-year interval between screening colonoscopies “could potentially be extended” to 15 years among patients without a family history of colorectal cancer and negative findings for CRC at the first colonoscopy, researchers reported. “For individuals without a family history of CRC, rescreening 10 years after the first normal colonoscopy examination is suggested by many widely
Source: www.healio.comCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 0FDA warns of ‘rare risk’ for thiopurine-related intrahepatic cholestasis of pregnancy - 5 day(s) ago
The FDA has issued a safety alert warning patients and health care providers of a “rare risk of intrahepatic cholestasis of pregnancy” linked to thiopurine use. The safety alert follows reported cases of intrahepatic cholestasis of pregnancy (ICP) among patients who were administered azathioprine, 6-mercaptopurine or 6-thioguanine as treatment for inflammatory bowel disease
Source: www.healio.comCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 0Olezarsen reduces triglycerides, pancreatitis events in familial chylomicronemia syndrome - 5 day(s) ago
Monthly olezarsen 80 mg significantly lowered triglyceride levels and also reduced incidence of acute pancreatitis vs. placebo in patients with familial chylomicronemia syndrome, according to a study in The New England Journal of Medicine. The investigational drug, a GalNAc3-conjugated antisense oligonucleotide, was granted orphan drug and breakthrough therapy designations by the FDA in February
Source: www.healio.comCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 5FDA approves high-concentration, citrate-free form of interchangeable biosimilar Cyltezo - 5 day(s) ago
The FDA has approved a citrate-free, high-concentration formulation of the interchangeable adalimumab biosimilar Cyltezo to treat multiple chronic inflammatory diseases, according to the manufacturer. As with the low-concentration (50 mg/mL) version of Cyltezo (adalimumab-adbm, Boehringer Ingelheim), the high-concentration formulation is approved for Crohn’s disease and ulcerative colitis,
Source: www.healio.comCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 4Honoring Stephen A. Harrison, MD, FAASLD: Pioneer who ‘propelled field of MASH forward’ - 5 day(s) ago
Col. Stephen A. Harrison, MD, FAASLD, a key leader in the field of hepatology who dedicated his life to caring for patients and developing treatments for liver disease, died on April 23. Harrison founded and chaired Pinnacle Clinical Research in San Antonio and was a pioneer in liver disease research, particularly in pursuit of treatment options for metabolic dysfunction-associated steatotic
Source: www.healio.comCategories: General Medicine News, GastroenterologyTweet
🚨NEW🚨 from @LancetGastroHep: Approximately two-thirds of patients with #Crohnsdisease who initially responded to anti-TNF lost response by 3️⃣ years, with researchers suggesting that higher drug concentrations at induction may improve outcomes. 🔽🔽 https://t.co/kZ2lim9ZYY